1. Home
  2. OMER vs NBXG Comparison

OMER vs NBXG Comparison

Compare OMER & NBXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Omeros Corporation

OMER

Omeros Corporation

N/A

Current Price

$13.29

Market Cap

1.2B

Sector

Health Care

ML Signal

N/A

Logo Neuberger Berman Next Generation Connectivity Fund Inc.

NBXG

Neuberger Berman Next Generation Connectivity Fund Inc.

N/A

Current Price

$12.64

Market Cap

1.3B

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
OMER
NBXG
Founded
1994
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Trusts Except Educational Religious and Charitable
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
1.3B
IPO Year
2008
2021

Fundamental Metrics

Financial Performance
Metric
OMER
NBXG
Price
$13.29
$12.64
Analyst Decision
Buy
Analyst Count
3
0
Target Price
★ $27.50
N/A
AVG Volume (30 Days)
★ 1.2M
249.1K
Earning Date
11-16-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
★ 98.15
N/A
EPS
★ 0.13
N/A
Revenue
★ $29,868,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$66.13
N/A
P/E Ratio
$107.77
★ N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$6.70
$12.32
52 Week High
$21.24
$17.43

Technical Indicators

Market Signals
Indicator
OMER
NBXG
Relative Strength Index (RSI) 30.78 28.51
Support Level $9.45 $12.32
Resistance Level $19.68 $15.83
Average True Range (ATR) 0.92 0.44
MACD -0.45 -0.09
Stochastic Oscillator 8.90 3.54

Price Performance

Historical Comparison
OMER
NBXG

About OMER Omeros Corporation

Omeros Corp is an inventive, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The company's clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program.

About NBXG Neuberger Berman Next Generation Connectivity Fund Inc.

Neuberger Berman Next Generation Connectivity Fund Inc. is a non-diversified, closed-end management investment company. The fund's investment objectives are to provide capital appreciation and income. Under normal market conditions, the Fund will invest at least 80% of its total assets in equity securities issued by U.S. and non-U.S. companies, in any market capitalization range, that is relevant to the theme of investing in NextGen Companies.

Share on Social Networks: